Abstract
There is a long and rich history of research and control in the field of schistosomiasis that has resulted in major scientific and public health accomplishments. Examples of such findings and accomplishments include immunologic regulation in chronic infections [1], the association of helminth infections with Th1-regulating Th2-type immune responses [2], the critical role of interleukin-13 in fibrogenesis [3], and the development and validation of the “dose pole” for determining praziquantel dosages in the field [4],[5]. Perhaps in part because of this broad and successful history, those who work on schistosomiasis come from a wide variety of backgrounds and interests. While such variety is enriching to the field, it sometimes results in diverse opinions about which of the many research opportunities should be pursued. Such diversity, we believe, has at times led to a divisiveness that has harmed overall progress in the field. Partly in response to such events, we have worked with as many of those interested in schistosomiasis as we could identify to develop what we feel is a comprehensive and cohesive agenda for schistosomiasis research (Image 1).
Highlights
We did not develop such an agenda as an attempt to work around or displace other efforts to organize schistosomiasis-related programs
The possible development of a comprehensive schistosomiasis research agenda was first discussed in a symposium at the annual meeting of the American Society of Tropical Medicine and Hygiene in Washington, D
The new agenda may appear to be nothing more than an exhaustive ‘‘laundry list’’ of every type of study needed on schistosomiasis
Summary
Summary: There is a long and rich history of research and control in the field of schistosomiasis that has resulted in major scientific and public health accomplishments. Examples of such findings and accomplishments include immunologic regulation in chronic infections [1], the association of helminth infections with Th1-regulating Th2-type immune responses [2], the critical role of interleukin-13 in fibrogenesis [3], and the development and validation of the ‘‘dose pole’’ for determining praziquantel dosages in the field [4,5]. Perhaps in part because of this broad and successful history, those who work on schistosomiasis come from a wide variety of backgrounds and interests While such variety is enriching to the field, it sometimes results in diverse opinions about which of the many research opportunities should be pursued. In response to such events, we have worked with as many of those interested in schistosomiasis as we could identify to develop what we feel is a comprehensive and cohesive agenda for schistosomiasis research (Image 1)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
